Logo

Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US

Share this

Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US

Shots:

  • Nanobiotix launches a new subsidiary- Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability- toxicity- and efficacy in the healthcare system in France & the US
  • Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received marketing approval in Europe
  • Curadigm technology increases the efficacy at current doses- decreases toxicity & cost- allowing to utilize new approaches for drug designing and is presented at AACR 2019

Ref: GlobeNewsWire | Image: My French Startup

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions